OM Stock Overview
A medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Outset Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$5.96 |
| 52 Week Low | US$0.44 |
| Beta | 2.16 |
| 1 Month Change | 47.88% |
| 3 Month Change | 93.65% |
| 1 Year Change | -80.59% |
| 3 Year Change | -97.56% |
| 5 Year Change | n/a |
| Change since IPO | -98.17% |
Recent News & Updates
Further Upside For Outset Medical, Inc. (NASDAQ:OM) Shares Could Introduce Price Risks After 32% Bounce
Nov 08
Outset Medical, Inc. (NASDAQ:OM) Might Not Be As Mispriced As It Looks After Plunging 27%
Sep 24Recent updates
Further Upside For Outset Medical, Inc. (NASDAQ:OM) Shares Could Introduce Price Risks After 32% Bounce
Nov 08Outset Medical, Inc. (NASDAQ:OM) Might Not Be As Mispriced As It Looks After Plunging 27%
Sep 24Outset Medical, Inc. (NASDAQ:OM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 11Outset Medical, Inc. (NASDAQ:OM) Stock Rockets 25% But Many Are Still Ignoring The Company
Jul 17Outset Medical: Expecting Accelerated Growth And Reduced Cash Burn Going Forward
May 28Outset Medical, Inc.'s (NASDAQ:OM) CEO Compensation Is Looking A Bit Stretched At The Moment
May 23Investors Still Aren't Entirely Convinced By Outset Medical, Inc.'s (NASDAQ:OM) Revenues Despite 30% Price Jump
May 10Not Many Are Piling Into Outset Medical, Inc. (NASDAQ:OM) Stock Yet As It Plummets 29%
Feb 14Outset Medical, Inc.'s (NASDAQ:OM) Earnings Haven't Escaped The Attention Of Investors
Jun 09Outset Medical: Tablo Ship Hold A Key Overhang To Unlock Risk Capital
Sep 20Outset Medical awarded VA contract for hemodialysis
Aug 15Outset Medical jumps 24% after 2Q results as FDA clears hemodialysis system
Aug 01Outset Medical: Margins Leave No Tangible Value Flow, Pricing 18% Downside
Jul 06Shareholder Returns
| OM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -8.3% | -3.4% | -3.5% |
| 1Y | -80.6% | 9.0% | 22.1% |
Return vs Industry: OM underperformed the US Medical Equipment industry which returned 11.2% over the past year.
Return vs Market: OM underperformed the US Market which returned 24% over the past year.
Price Volatility
| OM volatility | |
|---|---|
| OM Average Weekly Movement | 16.4% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OM's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 480 | Leslie Trigg | www.outsetmedical.com |
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform.
Outset Medical, Inc. Fundamentals Summary
| OM fundamental statistics | |
|---|---|
| Market cap | US$53.59m |
| Earnings (TTM) | -US$140.94m |
| Revenue (TTM) | US$114.73m |
0.5x
P/S Ratio-0.4x
P/E RatioIs OM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OM income statement (TTM) | |
|---|---|
| Revenue | US$114.73m |
| Cost of Revenue | US$79.20m |
| Gross Profit | US$35.53m |
| Other Expenses | US$176.47m |
| Earnings | -US$140.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 30.97% |
| Net Profit Margin | -122.84% |
| Debt/Equity Ratio | 412.3% |
How did OM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 10:38 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Outset Medical, Inc. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |